Docetaxel rechallenge after a first response in non-resistant metastatic breast cancer: Significant activity with manageable toxicity

Breast Cancer Research and Treatment

Volumn 134, Issue 1, 2012, Pages 325-332

  Toulmonde, M ^a   Madranges, N ^a   Brouste, V ^a   Donamaria, C ^a   MacGrogan, G ^a   Durand, M ^a   Bonnefoi, H ^a   Mauriac, L ^a   Debled, M ^a  

^a INSTITUT BERGONIÉ   (France)

Author keywords

Docetaxel; Metastatic breast cancer; Retreatment; Taxane

Indexed keywords

ANTHRACYCLINE; CA 15-3 ANTIGEN; CAPECITABINE; DOCETAXEL; NAVELBINE;

ADULT; AGED; ARTICLE; ASTHENIA; BLOOD TOXICITY; BREAST CANCER; CANCER RESISTANCE; CONTROLLED STUDY; DISEASE COURSE; DRUG ACTIVITY; DRUG EFFICACY; DRUG RESPONSE; DRUG WITHDRAWAL; EDEMA; FEBRILE NEUTROPENIA; FEMALE; FLUID RETENTION; HUMAN; MAJOR CLINICAL STUDY; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NAIL DISEASE; NEUROPATHY; NEUTROPENIA; OVERALL SURVIVAL; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SIDE EFFECT;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CARCINOMA, LOBULAR; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; MIDDLE AGED; RETROSPECTIVE STUDIES; TAXOIDS; TREATMENT OUTCOME;

EID: 84863983162     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-012-2060-2     Document Type: Article

References (33)

1. D Ghersi N Wilcken RJ Simes 2005 A systematic review of taxane-containing regimens for metastatic breast cancer Br J Cancer 93 293 301 16052223 10.1038/sj.bjc.6602680 1:CAS:528:DC%2BD2MXmvFensL0%3D
2. P Fumoleau B Chevallier P Kerbrat Y Krakowski JL Misset C Maugard-Louboutin V Dieras N Azli N Bougon A Riva H Roche 1996 A multicentre phase II study of the efficacy and safety of docetaxel as first-line treatment of advanced breast cancer: report of the Clinical Screening Group of the EORTC Ann Oncol 7 165 171 8777173 10.1093/oxfordjournals.annonc.a010544 1:STN:280:DyaK283mt1ejsw%3D%3D
3. CA Hudis AD Seidman JP Crown C Balmaceda R Freilich TA Gilewski TB Hakes V Currie DE Lebwohl J Baselga G Raptis M Gollub M Robles R Bruno L Norton 1996 Phase II and pharmacologic study of docetaxel as initial chemotherapy for metastatic breast cancer J Clin Oncol 14 58 65 8558221 1:CAS:528: DyaK28XhtVOjtrc%3D
4. ME Trudeau EA Eisenhauer BP Higgins F Letendre WS Lofters BD Norris TA Vandenberg F Delorme AM Muldal 1996 Docetaxel in patients with metastatic breast cancer: a phase II study of the National Cancer Institute of Canada-Clinical Trials Group J Clin Oncol 14 422 428 8636752 1:CAS:528:DyaK28XhsV2lsbw%3D
5. J Bonneterre H Roche A Monnier JP Guastalla M Namer P Fargeot S Assadourian 2002 Docetaxel vs. 5-fluorouracil plus vinorelbine in metastatic breast cancer after anthracycline therapy failure Br J Cancer 87 1210 1215 12439707 10.1038/sj.bjc.6600645 1:CAS:528:DC%2BD38XoslGlt7w%3D
6. S Chan K Friedrichs D Noel T Pinter S Van Belle D Vorobiof R Duarte M Gil Gil I Bodrogi E Murray L Yelle G von Minckwitz S Korec P Simmonds F Buzzi R Gonzalez Mancha G Richardson E Walpole M Ronzoni M Murawsky M Alakl A Riva J Crown 1999 Prospective randomized trial of docetaxel versus doxorubicin in patients with metastatic breast cancer J Clin Oncol 17 2341 2354 10561296 1:CAS:528:DyaK1MXltlylt70%3D
7. JM Nabholtz HJ Senn WR Bezwoda D Melnychuk L Deschenes J Douma TA Vandenberg B Rapoport R Rosso V Trillet-Lenoir J Drbal A Molino JW Nortier DJ Richel T Nagykalnai P Siedlecki N Wilking JY Genot PS Hupperets F Pannuti D Skarlos EM Tomiak M Murawsky M Alakl M Aapro, et al. 1999 Prospective randomized trial of docetaxel versus mitomycin plus vinblastine in patients with metastatic breast cancer progressing despite previous anthracycline-containing chemotherapy. 304 Study Group J Clin Oncol 17 1413 1424 10334526 1:CAS:528:DyaK1MXjsF2msrc%3D
8. J Sjostrom C Blomqvist H Mouridsen A Pluzanska S Ottosson-Lonn NO Bengtsson B Ostenstad I Mjaaland M Palm-Sjovall E Wist V Valvere H Anderson J Bergh 1999 Docetaxel compared with sequential methotrexate and 5-fluorouracil in patients with advanced breast cancer after anthracycline failure: a randomised phase III study with crossover on progression by the Scandinavian Breast Group Eur J Cancer 35 1194 1201 10615229 10.1016/S0959-8049(99)00122-7 1:CAS:528:DyaK1MXlvFWjur0%3D
9. DW Miles A Chan LY Dirix J Cortes X Pivot P Tomczak T Delozier JH Sohn L Provencher F Puglisi N Harbeck GG Steger A Schneeweiss AM Wardley A Chlistalla G Romieu 2010 Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer J Clin Oncol 28 3239 3247 20498403 10.1200/JCO.2008.21.6457 1:CAS:528:DC%2BC3cXhtVajur3P
10. NJ Robert V Dieras J Glaspy AM Brufsky I Bondarenko ON Lipatov EA Perez DA Yardley SY Chan X Zhou SC Phan J O'Shaughnessy 2011 RIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer J Clin Oncol 29 1252 1260 21383283 10.1200/JCO.2010.28.0982 1:CAS:528:DC%2BC3MXntlKlsb8%3D
11. JE Cortes R Pazdur 1995 Docetaxel J Clin Oncol 13 2643 2655 7595719 1:CAS:528:DyaK2MXpsVSltr8%3D
12. BM Donato L Burns V Willey M Cohenuram S Oliveria MU Yood 2010 Treatment patterns in patients with advanced breast cancer who were exposed to an anthracycline, a taxane, and capecitabine: a descriptive report Clin Ther 32 546 554 20399992 10.1016/j.clinthera.2010.03.007 1:CAS:528:DC%2BC3cXosVajsrs%3D
13. J Jassem C Carroll SE Ward E Simpson D Hind 2009 The clinical efficacy of cytotoxic agents in locally advanced or metastatic breast cancer patients pretreated with an anthracycline and a taxane: a systematic review Eur J Cancer 45 2749 2758 19615886 10.1016/j.ejca.2009.05.035 1:CAS:528:DC%2BD1MXhtlSqsLzL
14. A Dufresne X Pivot C Tournigand T Facchini T Altweegg L Chaigneau A De Gramont 2008 Impact of chemotherapy beyond the first line in patients with metastatic breast cancer Breast Cancer Res Treat 107 275 279 17380382 10.1007/s10549-007-9550-7 1:CAS:528:DC%2BD2sXhsVarur3E
15. U Banerji A Kuciejewska S Ashley G Walsh M O'Brien S Johnston I Smith 2007 Factors determining outcome after third line chemotherapy for metastatic breast cancer Breast 16 359 366 17509879 10.1016/j.breast.2007.01.004
16. A de Gramont M Buyse JC Abrahantes T Burzykowski E Quinaux A Cervantes A Figer G Lledo M Flesch L Mineur E Carola PL Etienne F Rivera I Chirivella N Perez-Staub C Louvet T Andre I Tabah-Fisch C Tournigand 2007 Reintroduction of oxaliplatin is associated with improved survival in advanced colorectal cancer J Clin Oncol 25 3224 3229 17664470 10.1200/JCO.2006.10.4380
17. M Fung-Kee-Fung T Oliver L Elit A Oza HW Hirte P Bryson 2007 Optimal chemotherapy treatment for women with recurrent ovarian cancer Curr Oncol 14 195 208 17938703 10.3747/co.2007.148 1:STN:280:DC%2BD2snhsVGitw%3D%3D
18. C Buonerba G Palmieri G Di Lorenzo 2010 Docetaxel rechallenge in castration-resistant prostate cancer: scientific legitimacy of common clinical practice Eur Urol 58 636 637 20580484 10.1016/j.eururo.2010.06.025
19. JC Eymard S Oudard G Gravis JM Ferrero C Theodore F Joly F Priou I Krakowski A Zannetti L Thill P Beuzeboc 2010 Docetaxel reintroduction in patients with metastatic castration-resistant docetaxel-sensitive prostate cancer: a retrospective multicentre study BJU Int 106 974 978 20230389 10.1111/j.1464-410X.2010.09296.x 1:CAS:528:DC%2BC3cXhsVSksrfE
20. Y Loriot C Massard M Gross-Goupil M Di Palma B Escudier A Bossi A Chauchereau K Fizazi 2010 The interval from the last cycle of docetaxel-based chemotherapy to progression is associated with the efficacy of subsequent docetaxel in patients with prostate cancer Eur J Cancer 46 1770 1772 20483588 10.1016/j.ejca.2010.04.010 1:CAS:528:DC%2BC3cXntlajtb8%3D
21. P Therasse SG Arbuck EA Eisenhauer J Wanders RS Kaplan L Rubinstein J Verweij M Van Glabbeke AT van Oosterom MC Christian SG Gwyther 2000 New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada J Natl Cancer Inst 92 205 216 10655437 10.1093/jnci/92.3.205 1:STN:280:DC%2BD3c7it1Gitg%3D%3D
22. KL Cheung AJ Evans JF Robertson 2001 The use of blood tumour markers in the monitoring of metastatic breast cancer unassessable for response to systemic therapy Breast Cancer Res Treat 67 273 278 11561773 10.1023/A:1017909727019 1:STN:280:DC%2BD3Mrhtl2lsQ%3D%3D
23. KL Cheung CR Graves JF Robertson 2000 Tumour marker measurements in the diagnosis and monitoring of breast cancer Cancer Treat Rev 26 91 102 10772967 10.1053/ctrv.1999.0151 1:STN:280:DC%2BD3c3jvVagsg%3D%3D
24. BT Hennessy AM Gauthier LB Michaud G Hortobagyi V Valero 2005 Lower dose capecitabine has a more favorable therapeutic index in metastatic breast cancer: retrospective analysis of patients treated at M. D. Anderson Cancer Center and a review of capecitabine toxicity in the literature Ann Oncol 16 1289 1296 15890665 10.1093/annonc/mdi253 1:STN:280:DC%2BD2MzotFamug%3D%3D
25. A Moreno-Aspitia EA Perez 2009 Anthracycline- and/or taxane-resistant breast cancer: results of a literature review to determine the clinical challenges and current treatment trends Clin Ther 31 1619 1640 19808124 10.1016/j.clinthera.2009.08.005 1:CAS:528:DC%2BD1MXht12gs77E
26. J Cortes J O'Shaughnessy D Loesch JL Blum LT Vahdat K Petrakova P Chollet A Manikas V Dieras T Delozier V Vladimirov F Cardoso H Koh P Bougnoux CE Dutcus S Seegobin D Mir N Meneses J Wanders C Twelves 2011 Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study Lancet 377 914 923 21376385 10.1016/S0140-6736(11)60070-6 1:CAS:528:DC%2BC3MXjtFWgs7c%3D
27. C Palmieri J Krell CR James C Harper-Wynne V Misra S Cleator D Miles 2010 Rechallenging with anthracyclines and taxanes in metastatic breast cancer Nat Rev Clin Oncol 7 561 574 20808300 10.1038/nrclinonc.2010.122 1:CAS:528:DC%2BC3cXht1ajt7jJ
28. YC Lin HK Chang CH Wang JS Chen CC Liaw 2000 Single-agent docetaxel in metastatic breast cancer patients pre-treated with anthracyclines and paclitaxel: partial cross-resistance between paclitaxel and docetaxel Anticancer Drugs 11 617 621 11081452 10.1097/00001813-200009000-00003 1:CAS:528: DC%2BD3cXnsl2gsr0%3D
29. EA Perez CL Vogel DH Irwin JJ Kirshner R Patel 2001 Multicenter phase II trial of weekly paclitaxel in women with metastatic breast cancer J Clin Oncol 19 4216 4223 11709565 1:CAS:528:DC%2BD38XhslWqtA%3D%3D
30. AD Seidman D Hochhauser M Gollub B Edelman TJ Yao CA Hudis P Francis D Fennelly TA Gilewski ME Moynahan V Currie J Baselga W Tong M O'Donaghue R Salvaggio L Auguste D Spriggs L Norton 1996 Ninety-six-hour paclitaxel infusion after progression during short taxane exposure: a phase II pharmacokinetic and pharmacodynamic study in metastatic breast cancer J Clin Oncol 14 1877 1884 8656256 1:CAS:528:DyaK28XjslOrsrk%3D
31. T Taguchi T Aihara Y Takatsuka E Shin K Motomura H Inaji S Noguchi 2004 Phase II study of weekly paclitaxel for docetaxel-resistant metastatic breast cancer in Japan Breast J 10 509 513 15569207 10.1111/j.1075-122X.2004.21555.x 1:CAS:528:DC%2BD2cXhtFaktbvN
32. V Valero SE Jones DD Von Hoff DJ Booser RG Mennel PM Ravdin FA Holmes Z Rahman MW Schottstaedt JK Erban L Esparza-Guerra RH Earhart GN Hortobagyi HA Burris III 1998 A phase II study of docetaxel in patients with paclitaxel-resistant metastatic breast cancer J Clin Oncol 16 3362 3368 9779713 1:CAS:528:DyaK1cXmvFGrtbc%3D
33. K Yonemori N Katsumata H Uno K Matsumoto T Kouno S Tokunaga Y Yamanaka C Shimizu M Ando M Takeuchi Y Fujiwara 2005 Efficacy of weekly paclitaxel in patients with docetaxel-resistant metastatic breast cancer Breast Cancer Res Treat 89 237 241 15754121 10.1007/s10549-004-2184-0 1:CAS:528: DC%2BD2MXitVKlsbo%3D